|
Tumor Immunity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest that VASH2 plays an essential role in the metastasis of PDAC with multiple effects on both cancer cells and the tumor microenvironment, including tubulin detyrosination, tumor angiogenesis and evasion of tumor immunity.
|
31074083 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
VASH2 also stimulated invasion and chemotherapeutic resistance of PC cells and increased the proportion of cancer stem-like cells in PC cells.
|
30318866 |
2018 |
|
Tumor Angiogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Vasohibin 2 (VASH2) is identified as an angiogenic factor, and has been implicated in tumor angiogenesis, proliferation and epithelial-mesenchymal transition (EMT).
|
27867016 |
2017 |
|
Tumor Angiogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The knockdown of VASH2 showed little effect on the proliferation of cancer cells in vitro but notably inhibited tumor growth, peritoneal dissemination, and tumor angiogenesis in a murine xenograft model.
|
22826464 |
2012 |
|
Tumor Angiogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Knockout of Vash2 caused minimal reduction of tumor angiogenesis but a significant decrease in cancer-associated fibroblasts (CAF) in tumor stroma.
|
28960674 |
2017 |
|
Tumor Angiogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest that VASH2 plays an essential role in the metastasis of PDAC with multiple effects on both cancer cells and the tumor microenvironment, including tubulin detyrosination, tumor angiogenesis and evasion of tumor immunity.
|
31074083 |
2019 |
|
Tumor Angiogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.
|
24118388 |
2013 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that VASH2 is abnormally expressed in TNBC, indicating a novel and important role for VASH2 in TNBC malignant transformation.
|
28670379 |
2017 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that VASH2 is abnormally expressed in TNBC, indicating a novel and important role for VASH2 in TNBC malignant transformation.
|
28670379 |
2017 |
|
Stomach Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These results suggest that VASH2 plays an important role in gastric tumor progression via the accumulation of CAF accompanying upregulation of EREG and IL-11 expression.
|
28960674 |
2017 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
When Gan mice were crossed with the Vash2-deficient (Vash2<sup>LacZ/LacZ</sup> ) strain, gastric cancer formation was significantly suppressed in Vash2<sup>LacZ/LacZ</sup> Gan mice.
|
28960674 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to assess the prognostic values of VASH1 expression and VASH2 expression in esophageal squamous cell carcinoma (ESCC).
|
30250596 |
2018 |
|
Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Vasohibin-2 was recently identified as an important pro-angiogenesis factor in solid tumor and intracellular localization of its variants is important for elucidating the downstream mechanism(s) of its effects.
|
23615928 |
2013 |
|
Skin lesion
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The significantly decreased expression of PECAM1, PTGS1, FGD5, and MCAM at both mRNA and protein level (except VASH2 and STAB1) were demonstrated in mesenchymal stem cells from psoriatic skin lesions compared with non-lesional from healthy controls.
|
26748901 |
2016 |
|
Psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our microarray analysis suggested that the pro-angiogenic genes platelet endothelial cell adhesion molecule-1 (PECAM1), facio-genital dysplasia-5 (FGD5), prostaglandin-endoperoxide synthase-1 (PTGS1), melanoma cell adhesion molecule (MCAM), vasohibin-2 (VASH2), and stabilin-1 (STAB1) are differentially expressed in dermal mesenchymal stem cells in psoriasis.
|
26748901 |
2016 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Vasohibins (VASH1 and VASH2) are recently identified regulators of angiogenesis and cancer cell functions.
|
27879017 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related protein.
|
28327155 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
The knockdown of VASH2 showed little effect on the proliferation of cancer cells in vitro but notably inhibited tumor growth, peritoneal dissemination, and tumor angiogenesis in a murine xenograft model.
|
22826464 |
2012 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Vasohibin‑2 (VASH2) is an angiogenic factor, and has been previously reported to be a cancer‑related gene, with cytoplasmic and karyotypic forms.
|
24920244 |
2014 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Cytoplasmic VASH2 is associated with carcinoma angiogenesis and malignant transformation and promotes cancer growth.
|
26177649 |
2015 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Vasohibin-2 is mainly expressed in cancer cells, and has been implicated in the progression of cancer by inducing angiogenesis and tumor growth.
|
28064471 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
VASH2 also stimulated invasion and chemotherapeutic resistance of PC cells and increased the proportion of cancer stem-like cells in PC cells.
|
30318866 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Under hypoxia, both vasohibin-1 and vasohibin-2 expressions were significantly decreased in the distant metastasis cancer cell line Hs-746T, cultured with or without TAMs (P<0.001).
|
22438034 |
2012 |
|
PIGMENTARY DISORDER, RETICULATE, WITH SYSTEMIC MANIFESTATIONS
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A positive expression of VASH2 was identified in vascular endothelial cells of FVMs from PDR patients.
|
28882646 |
2017 |
|
Peritoneal dissemination
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that VASH2 expressed in serous ovarian carcinoma cells promoted tumor growth and peritoneal dissemination by promoting angiogenesis.
|
22826464 |
2012 |